296 results on '"Carlo Aul"'
Search Results
2. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
- Author
-
Tamara Alpermann, Susanne Schnittger, Christiane Eder, Frank Dicker, Manja Meggendorfer, Wolfgang Kern, Christoph Schmid, Carlo Aul, Peter Staib, Clemens-Martin Wendtner, Norbert Schmitz, Claudia Haferlach, and Torsten Haferlach
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2016
- Full Text
- View/download PDF
3. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group
- Author
-
Friederike Braulke, Uwe Platzbecker, Catharina Müller-Thomas, Katharina Götze, Ulrich Germing, Tim H. Brümmendorf, Florian Nolte, Wolf-Karsten Hofmann, Aristoteles A. N. Giagounidis, Michael Lübbert, Peter L. Greenberg, John M. Bennett, Francesc Solé, Mar Mallo, Marilyn L. Slovak, Kazuma Ohyashiki, Michelle M. Le Beau, Heinz Tüchler, Michael Pfeilstöcker, Thomas Nösslinger, Barbara Hildebrandt, Katayoon Shirneshan, Carlo Aul, Reinhard Stauder, Wolfgang R. Sperr, Peter Valent, Christa Fonatsch, Lorenz Trümper, Detlef Haase, and Julie Schanz
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%–20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34+) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34+ peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34+ blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913).
- Published
- 2015
- Full Text
- View/download PDF
4. Acute Myeloid Leukemia (AML): The Role of Intensive Induction Chemotherapy
- Author
-
Thomas Büchner, Wolfgang Hiddemann, Wolfgang E. Berdel, Bernhard Wörmann, Helmut Löffler, Claudia Schoch, Torsten Haferlach, Wolf-Dieter Ludwig, Georg Maschmeyer, Eva Lengelder, Peter Staib, Reinhard Andreesen, Leopold Balleisen, Detlef Haase, Hartmut Eimermacher, Andrea Schumacher, Carlo Aul, Herbert Rasche, Jens Uhlig, Andreas Grüneisen, Hans Edgar Reis, Joachim Hartlapp, Wolf-Dietrich Hirschmann, Hans-Josef Weh, Hermann-Josef Pielken, Winfried Gassmann, Maria-Cristina Sauerland, and Achim Heinecke for the German AML Cooperative Group
- Subjects
double induction ,high-dose AraC ,daunorubicin dosage ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Intensive induction therapy-in acute myeloid leukemia (AML), as in some other systemic malignancies- is a strategy fundamentally different from post-remission strategies. Approaches like consolidation treatment, prolonged mainte¬nance, and autologous or allogeneic transplantation in the first remission are directed against minimal residual disease with a malignant cell population having survived the induction treatment. In contrast, induction therapy deals with naive tumor cells possibly different in their sensitivity from their counterparts in remission. Therefore, in AML it has been suggested to introduce intensification strategies into the induction part of treatment as a new step after the preceding intensification steps in the post-remission part. As expected from the dose effects observed in post-remission treatment using more AraC or longer treatment, similar dose effects have been found in the induction treatment both by the incorporation of high-dose AraC and by the double induction strategy administered in patients up to 60 years of age. For example, patients with poor risk AML due to an unfavorable karyotype, high LDH in serum, or delayed response, benefited from double induction containing high-dose AraC by a longer survival as compared to that from standard dose AraC. A corresponding dose effect in the induction treatment has been found in patients of 60 years and older receiving daunorubicin 60 vs 30 mg/m2 as part of the TAD regimen with higher dosage. This treatment significantly increased the response and survival rate in older patients who represented a poor risk group as a whole. Thus, we could demonstrate, both in younger and older patients, that a poor prognosis can be improved by a more intensive induction therapy. High-dose AraC in induction, however, exhibits a cumulative toxicity in that a repetition of courses containing high-dose AraC in the post-remission period is associated with considerable myelotoxicity leading to longlasting aplasias of about 6 weeks. However, after intensive induction treatment, high-dose chemotherapy in remission may become practicable using autologous stem cell rescue and may contribute to a further improvement of the outcome in poor risk as well as average patients with AML. These approaches are currently investigated by the German AMLCG. While there are clear limitations in the intensity of antineoplastic treatment for AML, as for other systemic malignancies, some further intensification may be possible and effective.
- Published
- 2004
5. Acute Myeloid Leukemia (AML): The Role of Maintenance Chemo¬therapy
- Author
-
Thomas Büchner, Wolfgang Hiddemann, Wolfgang E. Berdel, Bernhard Wörmann, Helmut Löffler, Claudia Schoch, Torsten Haferlach, Wolf-Dieter Ludwig, Georg Maschmeyer, Eva Lengelder, Peter Staib, Reinhard Andreesen, Leopold Balleisen, Detlef Haase, Hartmut Eimermacher, Carlo Aul, Herbert Rasche, Jens Uhlig, Andreas Grüneisen, Hans Edgar Reis, Joachim Hartlapp, Wolf-Dietrich Hirschmann, Hans-Josef Weh, Hermann-Josef Pielken, Winfried Gassmann, Andrea Schumacher, Maria-Cristina Sauerland, and Achim Heinecke for the German AML Cooperative Group
- Subjects
maintenance therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Maintenance treatment for patients with acute myeloid leukemia (AML) in remission has recently been controversially discussed and even abandoned by several groups. An analysis of 16 published multicenter trials, however, revealed the highest probabilities of relapse free survival (RFS) in the range of 35-42 % at 4-5 years only in patients assigned to maintenance treatment when adult age and intent-to-treat conditions were considered. After having demonstrated a superior RFS from 3 year maintenance following standard dose consolidation over that from consolidation alone (p
- Published
- 2004
6. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes
- Author
-
Marta Fernandez-Mercado, Adam Burns, Andrea Pellagatti, Aristoteles Giagounidis, Ulrich Germing, Xabier Agirre, Felipe Prosper, Carlo Aul, Sally Killick, James S. Wainscoat, Anna Schuh, and Jacqueline Boultwood
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Interstitial deletion of chromosome 5q is the most common chromosomal abnormality in myelodysplastic syndromes. The catalogue of genes involved in the molecular pathogenesis of myelodysplastic syndromes is rapidly expanding and next-generation sequencing technology allows detection of these mutations at great depth. Here we describe the design, validation and application of a targeted next-generation sequencing approach to simultaneously screen 25 genes mutated in myeloid malignancies. We used this method alongside single nucleotide polymorphism-array technology to characterize the mutational and cytogenetic profile of 43 cases of early or advanced del(5q) myelodysplastic syndromes. A total of 29 mutations were detected in our cohort. Overall, 45% of early and 66.7% of advanced cases had at least one mutation. Genes with the highest mutation frequency among advanced cases were TP53 and ASXL1 (25% of patients each). These showed a lower mutation frequency in cases of 5q- syndrome (4.5% and 13.6%, respectively), suggesting a role in disease progression in del(5q) myelodysplastic syndromes. Fifty-two percent of mutations identified were in genes involved in epigenetic regulation (ASXL1, TET2, DNMT3A and JAK2). Six mutations had allele frequencies
- Published
- 2013
- Full Text
- View/download PDF
7. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
- Author
-
Li Wang, Carrie Fidler, Nandita Nadig, Aristoteles Giagounidis, Matteo G. Della Porta, Luca Malcovati, Sally Killick, Norbert Gattermann, Carlo Aul, Jacqueline Boultwood, and James S. Wainscoat
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background We undertook a genome wide single nucleotide polymorphism analysis of a spectrum of patients with myelodysplastic syndrome del(5q) in order to investigate whether additional genomic abnormalities occur. Single nucleotide polymorphism array analysis has been shown to detect not only gene deletions but also regions of uniparental disomy that can pinpoint particular regions for mutation analysis.Design and Methods We studied 42 cases of myelodysplastic syndrome with del(5q), comprising 21 patients with 5q- syndrome and 21 with del(5q) (not 5q- syndrome), and 45 healthy controls by genome wide single nucleotide polymorphism analysis with the 50K Affymetrix single nucleotide polymorphism arrays.Results The del(5q) was characterized in all cases. The commonly deleted region of the 5q- syndrome extends between the genes SH3TC2 (proximal boundary) and GLRA1 (distal boundary) and measures 2.9 Mb. Copy number changes in addition to the del(5q) were observed in 10 of 21 patients with del(5q) myelodysplastic syndrome but in none of the patients with the 5q- syndrome. A total of 63 regions of uniparental disomy greater than 2 Mb were detected in 40 of 42 patients, dispersed on 18/23 chromosomes. In the 5q- syndrome group 31 regions of uniparental disomy were identified in 19 of 21 patients, the largest one being 7.6 Mb. All 21 patients with del(5q) myelodysplastic syndrome had uniparental disomy; in total 32 regions of uniparental disomy were identified in the 21 patients, including six regions of uniparental disomy > 10 Mb. Eight recurrent regions of uniparental disomy were observed among the 42 patients. For eight patients we had T-cell DNA as a germline control and four recurrent regions of uniparental disomy were identified that were present only in the neutrophil and not T-cell DNA. One small region of uniparental disomy at 10p12.31-p12.2 was observed in four patients with the 5q- syndrome.Conclusions This study shows that regions of uniparental disomy greater than 2 Mb are found in the 5q-syndrome and del(5q) myelodysplastic syndrome, although large regions of uniparental disomy (>10 Mb) are only found in the latter group. The recurrent regions of uniparental disomy may indicate the position of novel leukemia-associated genes.
- Published
- 2008
- Full Text
- View/download PDF
8. Chronic myelomonocytic leukemia in the light of the WHO proposals
- Author
-
Ulrich Germing, Corinna Strupp, Sabine Knipp, Andrea Kuendgen, Aristoteles Giagounidis, Barbara Hildebrandt, Carlo Aul, Rainer Haas, Norbert Gattermann, and John M. Bennett
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p
- Published
- 2007
- Full Text
- View/download PDF
9. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
- Author
-
Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke, Georg Maschmeyer, Haifa Kathrin Al-Ali, Sebastian Schwind, Madlen Jentzsch, Michael Cross, Christoph Kahl, Hans-Heinrich Wolf, Herbert Sayer, Antje Schulze, Peter Dreger, Ute Hegenbart, Alwin Krämer, Christian Junghanss, Lars-Olof Mügge, Detlev Hähling, Carsten Hirt, Christian Späth, Norma Peter, Bernhard Opitz, Axel Florschütz, Kolja Reifenrath, Niklas Zojer, Sebastian Scholl, Wolfram Pönisch, Simone Heyn, Vladan Vucinic, Andreas Hochhaus, Carlo Aul, Aristoteles Giagounidis, Leopold Balleisen, Bernd Oldenkott, Peter Staib, Michael Kiehl, Wolfgang Schütte, Ralph Naumann, Hartmut Eimermacher, Bernd Dörken, Cristina Sauerland, Eva Lengfelder, Wolfgang Hiddemann, Bernhard Wörmann, Carsten Müller-Tidow, Hubert Serve, Christoph Schliemann, Rüdiger Hehlmann, Wolfgang E. Berdel, Markus Pfirrmann, Utz Krug, and Verena S. Hoffmann
- Subjects
Hematology ,General Medicine - Abstract
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the CSA (n = 132) or to the study group arms (n = 1154) of the AMLCG (TAD/HAM versus HAM/HAM ± G-CSF followed by TAD and maintenance) and the OSHO (intermediate-dose ara-C/mitoxantrone followed by ara-C/mitoxantrone). Median age of the 1147 eligible patients was 69 (range 60–87) years. CR/CRi status at 90 days was not significantly different between the CSA (54% (95%CI: 45–64)) and the study group arms (53% (95%CI: 47–60) and 59% (95%CI: 58–63)). The five-year event-free survival (EFS) probability (primary endpoint) was 6.2% (95%CI: 2.7–14.0) in the CSA, 7.6% (95%CI: 4.5–12.8) in study group A and 11.1% (95%CI: 9.0–13.7) in B. The 5-year OS was 17.2% (95%CI: 11.0–26.9), 17.0% (95%CI: 2.0–23.9), and 19.5% (95%CI: 16.7–22.8) in CSA, study group A and B, respectively. Neither study group differed significantly from the CSA regarding EFS, OS, or relapse-free survival. In multivariate analyses, allocation to the treatment strategy was not significantly associated with the time-to-event endpoints. The evaluation of more intensive treatment strategies did not show clinically relevant outcome differences when compared to CSA.
- Published
- 2023
10. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche
- Author
-
Guntram Buesche, Huesniye Teoman, Rebekka K. Schneider, Flavia Ribezzo, Benjamin L. Ebert, Aristoteles Giagounidis, Gudrun Göhring, Brigitte Schlegelberger, Oliver Bock, Arnold Ganser, Carlo Aul, Ulrich Germing, Hans Kreipe, and Hematology
- Subjects
Chromosome Aberrations ,Mice ,Macrophages ,Myelodysplastic Syndromes ,Animals ,Chromosomes, Human, Pair 5 ,Humans ,Anemia ,Hematology ,Chromosome Deletion ,Lenalidomide ,Thalidomide - Abstract
Br J Haematol 198(1), 114-130 (2022). doi:10.1111/bjh.18163, Published by Wiley-Blackwell, Oxford [u.a.]
- Published
- 2022
11. Supplement 2 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Discontinuations and dose reductions
- Published
- 2023
12. Supplement 8 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Quality of life
- Published
- 2023
13. Supplement 7 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Second primary malignancies
- Published
- 2023
14. Supplement 3 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Exposure and remissions
- Published
- 2023
15. Supplement 4 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Subgroup analysis by randomization strata II
- Published
- 2023
16. Supplement 6 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
AE incidence and severity
- Published
- 2023
17. Data from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Purpose:For multiple myeloma, high-dose chemotherapy and autologous blood stem-cell transplantation (ASCT) followed by lenalidomide maintenance (LenMT) at 10–15 mg/day is considered standard of care. However, dose reductions due to side effects are common and median LenMT doses achieved over time may remain lower. Dose response during LenMT has never been investigated.Patients and Methods:In a multicenter, randomized, open-label trial, patients with multiple myeloma after ASCT and high-dose lenalidomide consolidation therapy (CT) at 25 mg/day were randomized to receive LenMT at either 25 or 5 mg/day. Primary endpoint was progression-free survival (PFS).Results:Ninety-four patients (median age, 58 years) were randomized to either arm, with 22% having International Staging System (ISS) stage 3 and 22% being in complete remission (CR). After median follow-up of 46.7 months, median doses of 14.5 and 5 mg/day were achieved in the two arms; 53% of dose reductions occurring during CT. In the high- and the low-dose arm, median PFS was 44.8 and 33.0 months (HR, 0.65; 95% CI, 0.44–0.97; P = 0.032), 36% and 23% of patients had stringent CR as best response (P = 0.08), and 4-year OS was 79% and 67% (P = 0.16), respectively. Hematologic toxicity, grade ≥3 neutropenia, and infections were initially more common with LenMT 25 mg, but decreased after dose adjustments. SPM incidence and quality-of-life (QoL) scores in both arms were similar.Conclusions:LenMT dose correlated with efficacy and toxicity. High rates of dose reductions during CT argue against a high starting dose. However, continuous up- and down-titration for each patient to the current maximum tolerated dose is prudent.
- Published
- 2023
18. Supplement 1 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Guido Kobbe, Rainer Haas, Mustafa Kondakci, Ariane Dienst, Judith Strapatsas, Carlo Aul, Elias K. Mai, Ingrida Savickaite, Katarzyna Hauck, Svenja Liesenjohann, Julia Baier, Celina Gerrlich, David Lopez, Amelie Boquoi, Nicolaus Kroger, Mathias Rummel, Michael Heinsch, Hartmut Goldschmidt, Aristoteles Giagounidis, and Roland Fenk
- Abstract
Centers and enrolment
- Published
- 2023
19. Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center
- Author
-
Carlo Aul, Guido Kobbe, Jennifer Kaivers, Volker Runde, Judith Strapatsas, Thomas Schroeder, Josefine Stark, Aristoteles Giagounidis, Esther Schuler, Andrea Kündgen, Christina Rautenberg, Kathrin Nachtkamp, Corinna Strupp, Ulrich Germing, Rainer Haas, and Norbert Gattermann
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Population ,Eligibility Determination ,Cohort Studies ,Tertiary Care Centers ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,Clinical Trials as Topic ,business.industry ,Myelodysplastic syndromes ,Patient Selection ,Hematology ,medicine.disease ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,Cohort ,Inclusion and exclusion criteria ,Referral center ,Female ,business ,030215 immunology - Abstract
Participation in clinical trials may allow patients with MDS to gain access to therapies not otherwise available. However, access is limited by strict inclusion and exclusion criteria, reflecting academic or regulatory questions addressed by the respective studies. We performed a simulation in order to estimate the average proportion of MDS patients eligible for participation in a clinical trial. The simulation drew upon 1809 patients in the Dusseldorf MDS Registry whose clinical data allowed eligibility screening for a wide range of clinical trials. This cohort was assumed to be alive and available for study participation. The simulation also posited that all MDS trials (n = 47) conducted in our center between 1987 and 2016 were open for recruitment. In addition, study activities in the year 2016 were analyzed to determine the proportion of patients eligible for at least one of the 9 MDS trials open at that time. On average, each clinical trial was suitable for about 18 % of patients in the simulation cohort. Conversely, 34 % of the patients were eligible for at least one of the 9 clinical studies in 2016. Inclusion/exclusion criteria of studies initiated by the pharmaceutical industry excluded more than twice the fraction of patients compared with investigator initiated trials (potential inclusion of 10 % vs. 21 %, respectively). Karyotype (average exclusion rate 58 %), comorbidities (40 %), and prior therapies (55 %) were the main reasons for exclusion. We suggest that in- and exclusion criteria should be less restrictive, in order to meet the needs of the real-life population of elderly MDS patients.
- Published
- 2021
20. Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Author
-
Rainer Haas, Ingrida Savickaite, Judith Strapatsas, Carlo Aul, Hartmut Goldschmidt, Nicolaus Kröger, Mathias J. Rummel, Amelie Boquoi, Ariane Dienst, David Lopez, Celina Gerrlich, Svenja Liesenjohann, Julia Baier, Aristoteles Giagounidis, Mustafa Kondakci, Elias K. Mai, Michael Heinsch, Roland Fenk, K. Hauck, and Guido Kobbe
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Maximum Tolerated Dose ,medicine.medical_treatment ,Urology ,Neutropenia ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Maintenance therapy ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,030212 general & internal medicine ,Lenalidomide ,Multiple myeloma ,Chemotherapy ,Peripheral Blood Stem Cell Transplantation ,Dose-Response Relationship, Drug ,business.industry ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Transplantation ,Consolidation Chemotherapy ,Oncology ,Tolerability ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,business ,Multiple Myeloma ,medicine.drug - Abstract
Purpose: For multiple myeloma, high-dose chemotherapy and autologous blood stem-cell transplantation (ASCT) followed by lenalidomide maintenance (LenMT) at 10–15 mg/day is considered standard of care. However, dose reductions due to side effects are common and median LenMT doses achieved over time may remain lower. Dose response during LenMT has never been investigated. Patients and Methods: In a multicenter, randomized, open-label trial, patients with multiple myeloma after ASCT and high-dose lenalidomide consolidation therapy (CT) at 25 mg/day were randomized to receive LenMT at either 25 or 5 mg/day. Primary endpoint was progression-free survival (PFS). Results: Ninety-four patients (median age, 58 years) were randomized to either arm, with 22% having International Staging System (ISS) stage 3 and 22% being in complete remission (CR). After median follow-up of 46.7 months, median doses of 14.5 and 5 mg/day were achieved in the two arms; 53% of dose reductions occurring during CT. In the high- and the low-dose arm, median PFS was 44.8 and 33.0 months (HR, 0.65; 95% CI, 0.44–0.97; P = 0.032), 36% and 23% of patients had stringent CR as best response (P = 0.08), and 4-year OS was 79% and 67% (P = 0.16), respectively. Hematologic toxicity, grade ≥3 neutropenia, and infections were initially more common with LenMT 25 mg, but decreased after dose adjustments. SPM incidence and quality-of-life (QoL) scores in both arms were similar. Conclusions: LenMT dose correlated with efficacy and toxicity. High rates of dose reductions during CT argue against a high starting dose. However, continuous up- and down-titration for each patient to the current maximum tolerated dose is prudent.
- Published
- 2020
21. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
- Author
-
Thomas Nösslinger, Michelle M. Le Beau, Peter L. Greenberg, José Cervera, Isabel Granada, Mar Mallo, Peter Valent, Christa Fonatsch, Ulrich Germing, Francesc Solé, Aristoteles Giagounidis, Michael Pfeilstöcker, John M. Bennett, Marylin L. Slovak, Julie Schanz, E. Luño, Michael Lübbert, Reinhard Stauder, Kazuma Ohyashiki, Otto Krieger, Detlef Haase, Barbara Hildebrandt, and Carlo Aul
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Clone (cell biology) ,clonality ,Biology ,Somatic evolution in cancer ,Gastroenterology ,cytogenetics ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,MDS ,Genetics ,medicine ,Humans ,Risk factor ,Aged ,Retrospective Studies ,Chromosome Aberrations ,Myelodysplastic syndromes ,Clonal architecture ,Hazard ratio ,Cytogenetics ,Prognosis ,medicine.disease ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Female ,abnormalities ,prognosis ,030215 immunology - Abstract
The study analyzes the clonal architecture and the abnormalities involved in a series of 191 patients with myelodysplastic syndromes (MDS) and 2-3 clonal abnormalities. All patients were extracted from an international database. The patients were classified into six clonal subtypes (2A-3C) based on the number of abnormalities and the presentation of unrelated clones (UC) and/or a clonal evolution. UC were detected in 23/191 patients (12%). The composition of UC showed great variability. The only recurrent combination of abnormalities was del(5q) and + 8 in 8 of 23 patients (35%). In patients with clonal evolution, the clone size of the primary and secondary clone varied: Patients with -7 and + 8 in the primary clone showed a larger primary and a smaller secondary clone (-7: median 74% vs 10%; +8 73% vs 18%) while patients with del(5q) in the primary clone showed a smaller primary and a larger secondary clone (33% vs 61%). Univariate and multivariate analyses showed no significant differences regarding overall or AML-free survival between the clonal subtypes. Only the subtype 3C (3 abnormalities and clonal evolution) was an independent risk factor for developing AML (Hazard Ratio 5.5 as compared to subtype 2A, P < .05). Finally, our study confirms that the number of abnormalities clearly defines a significant risk factor for overall- as well as AML-free survival. Importantly, in patients with more than one clone, the calculation of the number of abnormalities in the entire sample instead of the number of abnormalities per clone allows a higher prognostic accuracy.
- Published
- 2018
22. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?)
- Author
-
John M. Bennett, Corinna Strupp, Heinz Tuechler, Carlo Aul, and Ulrich Germing
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Cell Count ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Registries ,Young adult ,Acute myeloid leukemias ,Survival rate ,Erythroid Precursor Cells ,Retrospective Studies ,business.industry ,Myelodysplastic syndromes ,Retrospective cohort study ,Hematology ,Prognosis ,medicine.disease ,Survival Rate ,Leukemia, Myeloid, Acute ,Leukemia ,medicine.anatomical_structure ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Immunology ,Disease Progression ,Bone marrow ,Blast Crisis ,business ,030215 immunology - Abstract
The role of bone marrow dysplastic erythroid precursors (EP) in both MDS and AML has been the subject of considerable debate over the past several decades. We have analyzed a large series of adults with MDS and focused on whether any% of EP identified in the bone marrow aspirates of over 1400 patients selected from the Dusseldorf, Germany adult MDS Registry has prognostic relevance. The data was examined for varying% of blasts, the WHO prognostic MDS subtypes and the IPSS-R. We did not identify any adjustment of bone marrow blast percentage by%EP, incuding the 50% rule" developed by the FAB leukemia working group, to have a meaningful impact on outcome, either leukemic risk of progression or overall survival. There was a trend for a%EP
- Published
- 2016
23. Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL)
- Author
-
Susanne Saußele, Jörg Hasford, Michael Heuser, Gerhard Ehninger, Christoph Röllig, Hartmut Döhner, Martin Griesshammer, Martin Dugas, Arnold Ganser, Dietger Niederwieser, Thomas Büchner, Andreas Hochhaus, Nicola Gökbuget, Wolfgang Hiddemann, Andreas Reiter, Aristoteles Giagounidis, Rüdiger Hehlmann, Dieter Hoelzer, Carlo Aul, and Ute Kossak-Roth
- Subjects
Gynecology ,03 medical and health sciences ,European LeukemiaNet ,medicine.medical_specialty ,0302 clinical medicine ,business.industry ,030220 oncology & carcinogenesis ,Public Health, Environmental and Occupational Health ,Medicine ,business ,030215 immunology - Abstract
Im Jahr 1997 wurde durch den Zusammenschluss der fuhrenden Leukamie-Studiengruppen in Deutschland das Kompetenznetz Akute und Chronische Leukamien (KNL) gegrundet. Wichtige Resultate sind neue Kooperationsstudien und Forschungsprojekte, die Fortfuhrung und Erweiterung bestehender und die Grundung neuer nationaler Studiengruppen, die Verbesserung der Studieninfrastruktur sowie die Einrichtung von Patientenregistern und Biomaterialbanken. 2003 fuhrte das Konzept des KNL zur Grundung des European LeukemiaNet (ELN). In der Folge wurden in internationaler Kooperation zahlreiche europaische Managementleitlinien erarbeitet und mehrere landerubergreifende Projekte und Studien durchgefuhrt. Ziel des Netzes ist die Heilung der Leukamien durch kooperative Forschung.
- Published
- 2016
24. Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes
- Author
-
Carlo Aul, Gudrun Göhring, Arnold Ganser, Huesniye Teoman, Brigitte Schlegelberger, Aristoteles Giagounidis, Guntram Buesche, and Hans-Heinrich Kreipe
- Subjects
Male ,0301 basic medicine ,Poor prognosis ,Erythroblasts ,Anemia ,Myelodysplastic syndromes ,Hematology ,Biology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,Bone Marrow ,Myelodysplastic Syndromes ,hemic and lymphatic diseases ,Immunology ,medicine ,Humans ,Erythropoiesis ,Female ,Online Only Articles - Abstract
Erythropoiesis is arranged in erythroblastic islands (Ery-Is),[1][1] the specialized niche known for more than 50 years[2][2] in which erythroid precursors proliferate and differentiate. However, the significance of erythropoiesis in anemia, the leading symptom of myelodysplastic syndromes (MDS)
- Published
- 2016
25. Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- Author
-
S. Frühauf, R. Hansen, H. Munzinger, Urs Hess, X. Schiel, O. Stötzer, Holger Hebart, Mathias Hänel, S. Weidenhöfer, E. Jäger, H. Becker, Susanne Saußele, R. Gaeckler, F. Hartmann, Lorenz Trümper, W. Wuillemin, Thomas Illmer, W. Pommerien, Carlo Aul, P. le Coutre, W. Elsel, Otto Prümmer, A. Wehmeier, O. Klein, F. Schlegel, Sebastien Rinaldetti, D. Kingreen, Martin Bentz, J. Menzel, L. Hahn, R. Pihusch, Michael Schenk, Renate Arnold, Dietrich Kämpfe, B. Oldenkott, Alice Fabarius, M. Hahn, H. Eschenburg, A. Grote-Metke, M. Neise, Y. Dencausse, H. Köster, U. Vehling-Kaiser, M. Wattad, K. Stahlhut, H. Weischer, R. Moeller, Markus Pfirrmann, K. Neben, H. Tessen, A. Raghavachar, Peter Brossart, Hans-Heinrich Wolf, M. Hofknecht, Roland Schroers, Thomas Geer, Matthias Edinger, Axel R. Zander, R. Rudolph, F. Stegelmann, Winfried Gassmann, K. Ranft, A. Matzdorff, Christoph Scheid, M. Sosada, M. Sieber, G. Köchling, W. Fett, T. Herrmann, Rudolf Schlag, C. Maintz, S. Schanz, S. Hentschke, Peter Reichert, Dietrich W. Beelen, Alois Gratwohl, S. Schmitz, Michael Lauseker, Gabriela M. Baerlocher, H. P. Weidelich, F. Müller, B. Sievers, Alexander Kiani, J. Heßling, P. Majunke, W. Hollburg, D. Reschke, S. Wagner, B. Rendenbach, G. Käfer, W. Ludwig, Claudia Haferlach, A. Lochter, G. Baake, A. Schmalenbach, Y. Ko, R. Schwerdtfeger, Cornelius F. Waller, J. Mittermüller, Wolfgang E. Berdel, Walter Verbeek, C. Sperling, T. Fischer Huber, Karsten Spiekermann, C. Spohn, H. Pralle, Ch Scholz, C. Schelenz, H. Schick, A. D. Ho, Robert Dengler, C. Lunscken, D. Assman, H. Hoeffkes, A. Nusch, Hans-Walter Lindemann, B. Göttler, Günter Schlimok, H. Fiechtner, Patrick Wuchter, H. Forstbauer, C. Müller-Naendrup, J. Krauter, M. Planker, W. Langer, L. Schulz, Andreas Hochhaus, Hartmut Link, Philippe Schafhausen, Bernd Hertenstein, Andreas Neubauer, C. Schadeck-Gressel, M. Hoffknecht, L. Balleisen, A. Henzel, E. Ladda, Dieter K. Hossfeld, I. Blau, Jörg Hasford, V. Petersen, Christoph Nerl, M. Flaßhove, C. Lamberti, Stephan Kremers, Wassman, S. Korsten, Hans-Jochem Kolb, G. Adam, Michele Baccarani, M. Demandt, S. Al-Batran, S. Rösel, Jolanta Dengler, T. Neuhaus, Martin Griesshammer, B. Kempf, K. Josten, M. Sauer, W. Gröschel, U. Hieber, V. Runde, A. Urmersbach, Lutz P. Müller, Rüdiger Hehlmann, D. Linck, M. Hemeier, U. Martens, T. Kamp, S. Völkl, C. Diekmann, Andreas Burchert, T. Reiber, S. Bildat, J. Gmür, M. Uppenkamp, M. Simon, T. Zöller, Lothar Kanz, H. Strotkötter, N. Kalhori, R. Janz, Brigitte Schlegelberger, A. Hoyer, Wolfgang Seifarth, S. Stier, Katharina Kohlbrenner, J. Heymanns, J. Schleicher, Stefan W. Krause, M. de Wit, Antonio Pezzutto, D. Behringer, A. Lollert, H. Hitz, J. Janssen, G. Trenn, C. Lange, R. Depenbusch, A. Lindemann, H. Dietzfelbinger, B. Bechtel, B. Koch, B. Uebelmesser, U. Burkhardt, R. Fuchs, M. Schatz, S. Brettner, G. Heil, D. Hossfeld, Norbert Schmitz, C. Scheidegger, D. Reichert, M. Baldus, Michael J. Eckart, Axel A. Fauser, Lida Kalmanti, Birgit Spieß, Jiří Mayer, C. Ploger, C. A. Köhne, C. Priebe-Richter, C. Denzlinger, G. Doering, G. Springer, Tim H. Brümmendorf, Dominik Heim, Michael Kneba, I. M. Pfreundschuh, S. Jacki, M. Stauch, M. Kemmerling, Martin Wernli, A. Bartholomäus, Astghik Voskanyan, B. Sandritter, S. Fetscher, B. Goldmann, M. C. Goebler, C. Falge, Heinz Dürk, L. Fischer von Weikersthal, H. Baurmann, G. Ehninger, E. Schäfer, M. Schröder, F. Möller-Faßbender, K. Tajrobehkar, P. Schmidt, Christian A. Schmidt, A. Waladkhani, W. Freier, F. Henneke, and Beelen, Dietrich W. (Beitragende*r)
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Text mining ,business.industry ,Internal medicine ,Medizin ,medicine ,MEDLINE ,Hematology ,business - Abstract
Korrektur zu 10.1038/s41375-020-0826-9
- Published
- 2020
26. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group
- Author
-
Julie Schanz, Aristoteles Giagounidis, Detlef Haase, Peter Valent, Reinhard Stauder, Ulrich Germing, John M. Bennett, Uwe Platzbecker, Francesc Solé, Wolf-Karsten Hofmann, Peter L. Greenberg, Marilyn L. Slovak, Kazuma Ohyashiki, Carlo Aul, Michael Pfeilstöcker, Heinz Tüchler, Barbara Hildebrandt, Catharina Müller-Thomas, Katharina Götze, Ulrike Bacher, Christa Fonatsch, Friederike Braulke, Lorenz Trümper, Michael Lübbert, and Michelle M. Le Beau
- Subjects
Genetics ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,Myelodysplastic syndromes ,Karyotype ,Biology ,medicine.disease ,Gastroenterology ,ETV6 ,medicine.anatomical_structure ,Internal medicine ,medicine ,Bone marrow ,Abnormality ,Prospective cohort study ,Chromosome 12 ,Fluorescence in situ hybridization - Abstract
In myelodysplastic syndromes (MDS), deletion of the short arm of chromosome 12 (del(12p)) is usually a small abnormality, rarely detected as a single aberration by chromosome banding analysis (CBA) of bone marrow metaphases. Del(12p) has been described in 0.6 to 5% of MDS patients at initial diagnosis and is associated with a good to intermediate prognosis as a sole anomaly according to current scoring systems. Here, we present the results of a systematic del(12p) testing in a German prospective diagnostic study (clinicaltrials.gov: NCT01355913) on 367 MDS patients in whom CD34+ peripheral blood cells were analysed for the presence of del(12p) by sequential fluorescence in situ hybridization (FISH) analyses. A cohort of 2,902 previously published MDS patients diagnosed by CBA served as control. We demonstrate that, using a sensitive FISH technique, 12p deletion occurs significantly more frequently in MDS than previously described (7.6% by CD34+ PB-FISH vs. 1.6% by CBA, P < 0.001) and is often associated with other aberrations (93% by CD34+ PB-FISH vs. 60% by CBA). Additionally, the detection rate can be increased by repeated analyses in a patient over time which is important for the patient´s prognosis to distinguish a sole anomaly from double or complex aberrations. To our knowledge, this is the first study to screen for 12p deletions with a suitable probe for ETV6/TEL in 12p13. Our data suggest that the supplement of a probe for the detection of a 12p deletion to common FISH probe panels helps to avoid missing a del(12p), especially as part of more complex aberrations.
- Published
- 2015
27. Change of prognosis of patients with myelodysplastic syndromes during the last 30 years
- Author
-
Judith Neukirchen, Kathrin Nachtkamp, Ulrich Germing, Rainer Haas, Aristoteles Giagounidis, Carlo Aul, Guido Kobbe, Andrea Kuendgen, Jennifer Schemenau, and Corinna Strupp
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Pediatrics ,business.industry ,Myelodysplastic syndromes ,Hematology ,Prognosis ,medicine.disease ,Survival Analysis ,Surgery ,Oncology ,Treatment modality ,Myelodysplastic Syndromes ,medicine ,Humans ,Female ,business ,Retrospective Studies - Abstract
During the last years, more and more treatment modalities are available for MDS patients. Therefore, we were interested if this is reflected in an improvement of the outcome of the patients. We analyzed the survival and rate of leukemic progression of 4147 patients from the Duesseldorf MDS registry diagnosed during the last 30 years and found an improvement of survival in those patients diagnosed after 2002 (30 vs. 23 months, p0.0001). In detail, the improvement of the prognosis was restricted to high-risk MDS patients diagnosed between 2002 and 2014 in comparison to the patient group diagnosed between 1982 and 2001 (19 vs. 13 months, p0.001), whereas the prognosis of low-risk MDS patients did not change significantly. The improvement of survival was still measurable after exclusion of RAEB-t patients and of those, that received an allogeneic stem cell transplantation. In line with this finding, we found a lower AML progression rate in the later diagnosed group. Unfortunately, we could not identify a clear reason for this finding but rather a multifactorial cause should be assumed. As death due to bleeding complications and infections was significantly lower, an improvement of BSC may be one of the underlying causes.
- Published
- 2015
28. Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes
- Author
-
Judith Neukirchen, Petra Reinecke, Stefan Braunstein, Carlo Aul, Stephan Baldus, Kathrin Nachtkamp, Corinna Strup, Ulrich Germing, Rainer Haas, Sabine Blum, Martin Anlauf, Norbert Gattermann, and Jennifer Schemenau
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Concordance ,Bone Marrow ,Fibrosis ,hemic and lymphatic diseases ,Cytology ,medicine ,Humans ,Hematologic Tests ,business.industry ,Myelodysplastic syndromes ,Cytogenetics ,Histology ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Myelodysplastic Syndromes ,Disease Progression ,Female ,Histopathology ,Bone marrow ,business - Abstract
Background Myelodysplastic syndromes (MDS) present with a normo- or hyperplastic bone marrow in most cases. We aimed at a characterization of patients with different types of cellularity. Methods We assessed marrow cellularity both by histology and cytology in 1270 patients and analyzed hematologic, cytogenetic, and prognostic parameters accordingly. Results The concordance of the assessment of cellularity differed dramatically between histology and cytology as only 36.5% were described as hypocellular by both methods (P
- Published
- 2015
29. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML
- Author
-
Beate Betz, Corinna Strupp, Norbert Gattermann, Barbara Hildebrandt, Tobias Schroeder, Martina Rudelius, Esther Schuler, Ulrich Germing, Rainer Haas, Carlo Aul, and F. Frank
- Subjects
Neuroblastoma RAS viral oncogene homolog ,Male ,Cancer Research ,Myeloid ,Group A ,Monocytes ,chemistry.chemical_compound ,0302 clinical medicine ,Mutation Rate ,Bone Marrow ,hemic and lymphatic diseases ,Platelet ,Aged, 80 and over ,education.field_of_study ,Serine-Arginine Splicing Factors ,Esterases ,Nuclear Proteins ,Leukemia, Myelomonocytic, Chronic ,Hematology ,Middle Aged ,Prognosis ,DNA-Binding Proteins ,medicine.anatomical_structure ,Oncology ,RUNX1 ,030220 oncology & carcinogenesis ,Core Binding Factor Alpha 2 Subunit ,Female ,Adult ,Population ,Dioxygenases ,03 medical and health sciences ,Monocytosis ,Proto-Oncogene Proteins ,medicine ,Biomarkers, Tumor ,Humans ,Genetic Testing ,education ,Aged ,Cell Proliferation ,business.industry ,Myelodysplastic syndromes ,medicine.disease ,Repressor Proteins ,Genes, ras ,chemistry ,Myelodysplastic Syndromes ,Immunology ,Mutation ,business ,Carrier Proteins ,030215 immunology - Abstract
MDS patients may present with monocytic marrow proliferation not fulfilling criteria for CMML. We analyzed MDS patients with or without a marrow monocytic proliferation by following up the amount of monocytic proliferation and characterizing their molecular profile. 315 MDS patients of Duesseldorf MDS registry were divided into two groups: A) 183 patients with monocytic esterase positive cells in marrow and monocytes between 101 and 900/μl in blood and B) 132 patients without monocytic esterase positive cells in marrow and monocytes in blood ≤100/μl. Twenty patients of each group were screened with regard to ASXL1, TET2, RUNX1, SETBP1, NRAS, and SRSF2 using Illumina myeloid panel. Group A patients were older, had significantly higher WBC, hemoglobin levels, neutrophils and platelets. CMML evolution rates were 4.9% and 1.5%, respectively (p = n.s.). TET2, NRAS and SRFS2 mutation frequencies were higher in group A and four patients had coexisting TET2 and SRFS2 mutation, which was shown to be characteristic but not specific for CMML. MDS patients with marrow monocytic proliferation have a more CMML-like pheno- and genotype and develop CMML more often. Those patients could potentially be very early stages of CMML or represent a CMML-like myeloid neoplasma with marrow adherence of the monocytic cell population.
- Published
- 2017
30. Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group
- Author
-
Florian Nolte, Lorenz Trümper, Detlef Haase, Tim H. Brümmendorf, Wolf-Karsten Hofmann, Reinhard Stauder, Friederike Braulke, Peter L. Greenberg, Marilyn L. Slovak, Katharina Götze, Uwe Platzbecker, Mar Mallo, Michael Pfeilstöcker, Heinz Tüchler, Christa Fonatsch, Thomas Nösslinger, Katayoon Shirneshan, Francesc Solé, Wolfgang R. Sperr, Kazuma Ohyashiki, Carlo Aul, Barbara Hildebrandt, Michael Lübbert, Michelle M. Le Beau, Catharina Müller-Thomas, Peter Valent, John M. Bennett, Ulrich Germing, Julie Schanz, and Aristoteles Giagounidis
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Pathology ,Adolescent ,CD34 ,Antigens, CD34 ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Prospective Studies ,peripheral blood ,CD34+FISH ,cytogenetic risk groups ,Prospective cohort study ,Survival rate ,In Situ Hybridization, Fluorescence ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Chromosome Aberrations ,medicine.diagnostic_test ,business.industry ,Myelodysplastic syndromes ,Case-control study ,International Agencies ,Articles ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,3. Good health ,Survival Rate ,medicine.anatomical_structure ,International Prognostic Scoring System ,Case-Control Studies ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Female ,Bone marrow ,business ,Follow-Up Studies ,030215 immunology ,Fluorescence in situ hybridization - Abstract
International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34(+) peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34(+) blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913). peerReviewed
- Published
- 2014
31. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types
- Author
-
Aristoteles Giagounidis, Kathrin Nachtkamp, Ulrich Germing, Rainer Haas, Norbert Gattermann, Carlo Aul, John M. Bennett, Corinna Strupp, and Barbara Hildebrandt
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Adolescent ,MDS-RS-SLD ,World Health Organization ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Registries ,Aged ,Aged, 80 and over ,business.industry ,Group (mathematics) ,Myelodysplastic syndromes ,Hematology ,Middle Aged ,medicine.disease ,Survival Rate ,Leukemia, Myeloid, Acute ,Cell Transformation, Neoplastic ,Oncology ,030220 oncology & carcinogenesis ,Myelodysplastic Syndromes ,MDS-RS-MLD ,business ,Median survival ,030215 immunology - Abstract
Based on centrally diagnosed 3528 patients in the Dusseldorf registry, we validated the new proposals for the classification of the MDS by the WHO working group: 256 patients were diagnosed as MDSSLD (7,3%), 978 MDSMLD (27,7%), 227 MDS RS SLD (6,4%); 321 MDS RS MLD (9,1%), 159 MDS del(5q) (4,5%), 481 MDSEB 1 (13,6%), 620 MDSEB 2 (17,6%), and 148 MDS-U (4,2%). 352 patients (16,9% of the non blastic types) changed the category, mainly moving from RCMD to MDS RS MLD, RCUD and RCMD to MDS del(5q). Median survival times of the refined groups differed from more than 60 months in the MDSSLD (RS) groups, 37 months in the MDSMLD (RS) groups, 79 months of the MDS del(5q) group and 21 and 11 months in the MDSEB 1 and 2 groups, respectively. The difference between the groups with regard to the risk of AML evolution was also impressing. No major changes were made with regard to the MDS-U categories. In summary, the proposals of the WHO group for the classification of MDS are thoughtful, taking into account biologic parameters of the diseases, a more precise wording, to some extend pragmatic and feasible.
- Published
- 2016
32. Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial
- Author
-
Ingrida Savickaite, C. Matthias Wilk, Nicolaus Kroeger, Hartmut Goldschmidt, Judith Strapatsas, Rainer Haas, Roland Fenk, Mathias J. Rummel, Amelie Boquoi, Guido Kobbe, Carlo Aul, Ariane Dienst, Mustafa Kondakci, Aristoteles Giagounidis, Elias K. Mai, David Lopez y Niedenhoff, and Michael Heinsch
- Subjects
Change over time ,medicine.medical_specialty ,business.industry ,First line ,Immunology ,Autologous blood ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,High dose therapy ,Quality of life ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,business ,Multiple myeloma ,030215 immunology ,Lenalidomide ,medicine.drug - Abstract
Introduction The LenaMain study is a prospective, randomized, open label, multicenter phase III trial which included 188 patients 3 months after first-line high dose treatment and autologous stem cell transplantation (NCT number: NCT00891384). Patients were equally randomized to receive either 25 (n = 94, arm A) or 5 mg (n = 94, arm B) lenalidomide maintenance until disease progression following a uniform 6 months of 25 mg lenalidomide consolidation. Final analysis after follow-up of 46.7 months was presented at ASCO 2018 (#8016) demonstrating an extended event-free survival for arm A (11.8 months, p=0.032) and an about 10% increase of grade 3/4 infections per year as main toxicity. Here we report analysis of quality of life (QoL) data as secondary endpoint of the study. Materials & Methods The EORTC Quality of Life Questionnaire C30 (QLQ-C30) was collected at baseline and then monthly at every new cycle. The Global Health Status/Quality of Life (GHS/QoL) scale, the utility score and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning, disease symptoms, and adverse effects of treatment) were compared between groups using a mixed model for repeated measures. Results Baseline questionnaire compliance was excellent (95.7%) and declined over time (82%, 76%, 71%, 54%, 49% after consolidation and after year 1, 2, 3 and 4 of maintenance, respectively). At baseline, GHS/QoL (67/67) and utility (0.73/0.72) scores for arm A/B were generally high and did not differ between both arms. The median GHS/QoL change between consolidation baseline and maintenance baseline was -1%. GHS/QoL scores appear constant for both treatment arms at most time points in the first 2 years of maintenance. Relevant improvements ≥ 5 points were observed in 30% of patients while improvements ≥ 15 points were observed in 20% of patients. During the same time a similar percentage of patients had relevant ≥ 5 and ≥15 point deteriorations, with a general tendency for a slight increase at the end of year 2. Notably, a greater number of deteriorations was found in the 5 mg lenalidomide arm. Mean GHS/QoL was constant during maintenance with a slight decrease of Utility values remained constant during maintenance (change from baseline 0.003, p=0.9 at year 1; 0.02, p=0.7 at year 2) and the overall pattern in the change over time does not appear to show any clear differences between the two treatment arms. Looking at QLQ-C30 subgroup domains after two years of maintenance, we observed a significantly higher change from baseline for diarrhea in the 25 mg lenalidomide arm, which may be a long-term drug-related effect. Conversely, role functioning was also significantly better in patients treated within the 25 mg lenalidomide arm. Other subgroups did not show significant differences after the second year. Overall GHS/QOL scores were not significantly different in patients with CR vs. ≥ vgPR. Similarly, there was no statistical difference in patients on treatment for 1, 2, 3 or 4 years of maintenance or in patients suffering from grade 3/4 adverse events or not. Thus, neither disease activity, nor duration of treatment nor high-grade toxicity biased our results. Conclusion The LenaMain trial shows that maintenance treatment with 25 mg lenalidomide vs. 5 mg significantly prolongs event-free survival. QoL, as secondary objective, was not different between both treatment arms, even showing a trend for improved QoL in the 25 mg lenalidomide treatment arm. Thus, QoL was not governed by the higher rate of infectious toxicity during high-dose lenalidomide maintenance. Disclosures Boquoi: Amgen: Honoraria, Other: Travel grant; Bristol-Myers Squibb: Honoraria; Janssen: Other: Travel grant; Celgene: Other: Travel grant. Goldschmidt:Celgene: Consultancy, Honoraria, Research Funding; Chugai: Honoraria, Research Funding; ArtTempi: Honoraria; Takeda: Consultancy, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Research Funding; Novartis: Honoraria, Research Funding; Mundipharma: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Research Funding; Adaptive Biotechnology: Consultancy. Rummel:Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Mundipharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Eisai: Honoraria; Celgene: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Symbio: Honoraria. Kroeger:Sanofi: Honoraria; JAZZ: Honoraria; Novartis: Honoraria, Research Funding; Neovii: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Riemser: Honoraria, Research Funding. Mai:Celgene: Other: travel grant; Janssen: Honoraria, Other: Travel grant; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel grant, Research Funding; Onyx: Other: travel grant; Mundipharma: Other: travel grant. Kobbe:Amgen: Honoraria, Research Funding; Roche: Honoraria, Research Funding; Celgene: Honoraria, Other: Travel Support, Research Funding. Fenk:Amgen: Honoraria; Takeda: Honoraria; Celgene: Honoraria, Other: Travel grant, Research Funding; Bristol-Meyers Squibb: Honoraria, Other: travel grant; Janssen: Honoraria.
- Published
- 2018
33. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts
- Author
-
Ulrich Germing, Rainer Haas, Norbert Gattermann, Kathrin Nachtkamp, Andrea Kuendgen, Anna Maassen, Aristoteles Giagounidis, Barbara Hildebrandt, Carlo Aul, and Corinna Strupp
- Subjects
Adult ,Oncology ,Cancer Research ,medicine.medical_specialty ,Validation study ,Pediatrics ,Adolescent ,World Health Organization ,Internal medicine ,medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Cytopenia ,business.industry ,Myelodysplastic syndromes ,Retrospective cohort study ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Myelodysplastic Syndromes ,Who classification ,business - Abstract
In 2008, the WHO proposed changes in the classification of MDS regarding RCUD and MDS unclassifiable. We validated these proposals by using 2032 patients of the Düsseldorf MDS Registry. 10% of the patients had RCUD and 6% MDS-U. Among patients with RCUD, only 9% had RN and 6% had RT. There was no correlation between dysplastic cell line and type of cytopenia. There was no difference in prognosis between RCMD and MDS-U and between RA, RT, and RN. The separation of RA, RN, and RT is not justified suggesting a consolidation as RCUD. MDS-U should be integrated into RCMD.
- Published
- 2013
34. [Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]
- Author
-
Ute, Kossak-Roth, Susanne, Saußele, Carlo, Aul, Thomas, Büchner, Hartmut, Döhner, Martin, Dugas, Gerhard, Ehninger, Arnold, Ganser, Aristoteles, Giagounidis, Nicola, Gökbuget, Martin, Griesshammer, Jörg, Hasford, Michael, Heuser, Wolfgang, Hiddemann, Andreas, Hochhaus, Dieter, Hoelzer, Dietger, Niederwieser, Andreas, Reiter, Christoph, Röllig, and Rüdiger, Hehlmann
- Subjects
Government Programs ,Clinical Trials as Topic ,Biomedical Research ,Interinstitutional Relations ,Leukemia ,Quality Assurance, Health Care ,Germany ,Models, Organizational ,Humans ,Clinical Competence ,Program Evaluation - Abstract
The Competence Network "Acute and Chronic Leukemias" was founded in 1997 by the consolidation of the leading leukemia study groups in Germany. Key results are the development of new trials and cooperative studies, the setup of patient registries and biobanking facilities, as well as the improvement of study infrastructure. In 2003, the concept of the competence network contributed to the foundation of the European LeukemiaNet (ELN). Synergy with the ELN resulted in cooperation on a European and international level, standardization of diagnostics and treatment, and recommendations for each leukemia and interdisciplinary specialty. The ultimate goal of the network is the cure of leukemia through cooperative research.
- Published
- 2016
35. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
- Author
-
Clemens-Martin Wendtner, Christoph Schmid, Peter Staib, Claudia Haferlach, Carlo Aul, Norbert Schmitz, Frank Dicker, Torsten Haferlach, Tamara Alpermann, Susanne Schnittger, Christiane Eder, Wolfgang Kern, and Manja Meggendorfer
- Subjects
0301 basic medicine ,Adult ,Male ,Risk ,medicine.medical_specialty ,NPM1 ,Adolescent ,Oncogene Proteins, Fusion ,DNA Mutational Analysis ,Gene Expression ,Biology ,medicine.disease_cause ,DNA Methyltransferase 3A ,03 medical and health sciences ,0302 clinical medicine ,Molecular genetics ,medicine ,Humans ,DNA (Cytosine-5-)-Methyltransferases ,Online Only Articles ,WT1 Proteins ,Aged ,Aged, 80 and over ,Mutation ,Ccaat-enhancer-binding proteins ,Gene Expression Profiling ,Myeloid leukemia ,Nuclear Proteins ,Hematology ,Middle Aged ,Virology ,Molecular biology ,Survival Analysis ,Isocitrate Dehydrogenase ,Neoplasm Proteins ,Gene expression profiling ,Leukemia, Myeloid, Acute ,030104 developmental biology ,Isocitrate dehydrogenase ,fms-Like Tyrosine Kinase 3 ,030220 oncology & carcinogenesis ,Fms-Like Tyrosine Kinase 3 ,CCAAT-Enhancer-Binding Proteins ,Female ,Nucleophosmin - Abstract
Citation: Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, and Haferlach T. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia. Haematologica. 2015; 100:xxx doi:10.3324/haematol.2015.133819
- Published
- 2016
36. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
- Author
-
Michael Pfreundschuh, Matthias Edinger, Martin Wilhelm, Christiane Falge, Jörg Th. Fischer, Bernd Hertenstein, Markus Pfirrmann, Donald Bunjes, J Novotny, Susanne Schnittger, Michael Schatz, Artur Wehmeier, Andreas Hochhaus, Herbert G. Sayer, Ingo G.H. Schmidt-Wolf, Christoph Nerl, Claudia Haferlach, Susanne Saußele, Matthias Fabian, Martin C. Müller, Arnold Ganser, Joerg Hasford, Dieter K. Hossfeld, Anthony D. Ho, Hans-Jochem Kolb, Peter Staib, Herrmann Heimpel, Hartmut Döhner, Axel A. Fauser, Andreas Reiter, Michael Schenk, Renate Arnold, Gabriela M. Baerlocher, Rainer Schwerdtfeger, Carlo Aul, Rüdiger Hehlmann, Rolf Kuse, Thomas Kindler, Axel R. Zander, Gerald Wulf, Norbert Schmitz, Otto Prümmer, Karsten Spiekermann, Maria-Elisabeth Goebeler, Ute Berger, Anne Rosselet, Nicolaus Kröger, Dietrich W. Beelen, Alois Gratwohl, Günter Schlimok, Jiří Mayer, Andrzej Hellmann, Herrad Baurmann, Matthias Bormann, Hans Walter Lindemann, Christof Scheid, E. Schäfer, Guntram Büsche, and German CML Study Group
- Subjects
Male ,Cancer Research ,myeloid leukemia ,stem cell transplantation ,medicine.medical_treatment ,Medizin ,Salvage therapy ,Hematopoietic stem cell transplantation ,0302 clinical medicine ,hemic and lymphatic diseases ,Prospective Studies ,Prospective cohort study ,Aged, 80 and over ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Hematology ,Middle Aged ,Prognosis ,Tissue Donors ,3. Good health ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Original Article ,Female ,Adult ,Risk ,medicine.medical_specialty ,Adolescent ,Antineoplastic Agents ,610 Medicine & health ,03 medical and health sciences ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Family ,ddc:610 ,Protein Kinase Inhibitors ,Survival analysis ,Aged ,business.industry ,medicine.disease ,Survival Analysis ,Transplantation ,Imatinib mesylate ,Immunology ,business ,030215 immunology ,Chronic myelogenous leukemia - Abstract
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P
- Published
- 2016
37. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
- Author
-
Carlo Aul, Wolf-Karsten Hofmann, Achim Heinecke, Carsten Müller-Tidow, Cristina Sauerland, Stephanie Schneider, Heinz A. Horst, Wolfgang Hiddemann, Benjamin Hanfstein, Claudia Haferlach, Thomas Büchner, Wolfgang E. Berdel, Karsten Spiekermann, Jan Braess, Rüdiger Hehlmann, Beate Schultheis, Bernhard Wörmann, Susanne Schnittger, Hubert Serve, Philipp Erben, Torsten Haferlach, Karl-Anton Kreuzer, Eva Lengfelder, and Utz Krug
- Subjects
Male ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Arsenicals ,Leukocyte Count ,Maintenance therapy ,Arsenic Trioxide ,Leukemia, Promyelocytic, Acute ,immune system diseases ,Acute promyelocytic leukemia ,Bone Marrow ,Germany ,Antineoplastic Combined Chemotherapy Protocols ,Multicenter Studies as Topic ,Cumulative incidence ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,Remission Induction ,Age Factors ,Cytarabine ,Oxides ,Hematology ,General Medicine ,Early death ,Middle Aged ,Prognosis ,Leukemia ,Treatment Outcome ,Original Article ,Female ,medicine.drug ,Risk ,medicine.medical_specialty ,Tretinoin ,Disease-Free Survival ,Maintenance Chemotherapy ,Internal medicine ,medicine ,Humans ,Thioguanine ,neoplasms ,Aged ,Mitoxantrone ,Chemotherapy ,business.industry ,Daunorubicin ,medicine.disease ,Surgery ,Elderly patients ,Treatment ,Regimen ,business ,Follow-Up Studies - Abstract
Despite improvement of prognosis, older age remains a negative prognostic factor in acute promyelocytic leukemia (APL). Reports on disease characteristics and outcome of older patients are conflicting. We therefore analyzed 91 newly diagnosed APL patients aged 60 years or older (30 % of 305 adults with APL) registered by the German AML Cooperative Group (AMLCG) since 1994; 68 patients (75 %) were treated in studies, 23 (25 %) were non-eligible, and 31 % had high-risk APL. Fifty-six patients received induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin), and consolidation and maintenance therapy. Treatment intensification with a second induction cycle (high dose cytarabine, mitoxantrone; HAM) was optional (n = 14). Twelve patients were randomized to another therapy not considered in this report. The early death rate was 48 % in non-eligible and 19 % in study patients. With the AMLCG regimen, 7-year overall, event-free and relapse-free survival (RFS) and cumulative incidence of relapse were 45 %, 40 %, 48 %, and 24 %, respectively. In patients treated with TAD–HAM induction, 7-year RFS was superior (83 %; p = 0.006) compared to TAD only, and no relapse was observed. In our registered elderly patients, we see a high rate of non-eligibility for treatment in studies and of high-risk APL. In patients who can undergo a curative approach, intensified chemotherapy is highly effective, but is restricted to a selection of patients. Therefore, new less toxic treatment approaches with broader applicability are needed. Elderly patients might be a particular target group for concepts with arsenic trioxide.
- Published
- 2012
38. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
- Author
-
Georg Maschmeyer, W.-D. Ludwig, Hubert Serve, Leopold Balleisen, Peter Staib, Wolfgang E. Berdel, Christoph Schliemann, Karsten Spiekermann, Eckhard Thiel, Bernhard Wörmann, Th. Büchner, M Stelljes, Dennis Görlich, Carsten Müller-Tidow, Wolfgang Köpcke, Achim Heinecke, Susanne Schnittger, Aristoteles Giagounidis, Claudia Haferlach, Jan Braess, Andreas Grüneisen, Maria-Cristina Sauerland, Hartmut Eimermacher, Herbert Rasche, Wolfgang Kern, Robert Peter Gale, Wolfgang Hiddemann, Dietrich W. Beelen, A. Reichle, Carlo Aul, Ruediger Hehlmann, Utz Krug, Torsten Haferlach, and Eva Lengfelder
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Medizin ,Transplantation, Autologous ,Disease-Free Survival ,law.invention ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Survival rate ,Mitoxantrone ,business.industry ,Danazol ,Cytarabine ,Induction chemotherapy ,Hematology ,Induction Chemotherapy ,Middle Aged ,Aminoglutethimide ,Confidence interval ,Surgery ,Transplantation ,Survival Rate ,Leukemia, Myeloid, Acute ,Tamoxifen ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,business ,030215 immunology ,medicine.drug ,Stem Cell Transplantation - Abstract
We randomized 3375 adults with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome to test whether increasingly intensive chemotherapies assigned at study-entry and analyzed on an intent-to-treat basis improved outcomes. In total, 1529 subjects
- Published
- 2015
39. Causes of death in 2877 patients with myelodysplastic syndromes
- Author
-
Aristoteles Giagounidis, Carlo Aul, Norbert Gattermann, Andrea Kündgen, Corinna Strupp, Kathrin Nachtkamp, Barbara Hildebrandt, Romina Stark, Ulrich Germing, and Rainer Haas
- Subjects
Male ,Poor prognosis ,medicine.medical_specialty ,Primary care ,Disease ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Cause of Death ,medicine ,Humans ,Hemochromatosis ,Cause of death ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hematology ,business.industry ,Myelodysplastic syndromes ,General Medicine ,medicine.disease ,Surgery ,030220 oncology & carcinogenesis ,Heart failure ,Myelodysplastic Syndromes ,Female ,business ,030215 immunology ,Follow-Up Studies - Abstract
Patients with myelodysplastic syndromes face a poor prognosis. The exact causes of death have not been described properly in the past. We performed a retrospective analysis of causes of death using data of 3792 patients in the Dusseldorf registry who have been followed up for a median time of 21 months. Medical files as well as death certificates were screened and primary care physicians were contacted. Death after AML evolution, infection, and bleeding was considered to be clearly disease-related. Further categories of causes of death were heart failure, other possibly disease-related reasons, such as hemochromatosis, disease-independent reasons as well as cases with unclear causes of death. Median age at the time of diagnosis was 71 years. At the time of analysis, 2877 patients (75.9 %) had deceased. In 1212 cases (42.1 %), the exact cause of death could not be ascertained. From 1665 patients with a clearly documented cause of death, 1388 patients (83.4 %) succumbed directly disease-related (AML (46.6 %), infection (27.0 %), bleeding (9.8 %)), whereas 277 patients (16.6 %) died for reasons not directly related with myelodysplastic syndromes (MDS), including 132 patients with cardiac failure, 77 non-disease-related reasons, 23 patients with solid tumors, and 45 patients with possibly disease-related causes like hemochromatosis. Correlation with IPSS, IPSS-R, and WPSS categories showed a proportional increase of disease-related causes of death with increasing IPSS/IPSS-R/WPSS risk category. Likewise, therapy-related MDS were associated with a higher percentage of disease-related causes of death than primary MDS. This reflects the increasing influence of the underlying disease on the cause of death with increasing aggressiveness of the disease.
- Published
- 2015
40. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q
- Author
-
Carlo Aul, Lourdes Florensa, Otto Krieger, Christian Steidl, Guillermo Sanz, Claudia Haferlach, G. Garcia-Manero, Michael Lübbert, Reinhard Stauder, Rosa Collado, Peter Valent, Miguel A. Sanz, José Cervera, Thomas Noesslinger, Maria-Jose Calasanz, Julie Schanz, Kazuma Ohyashiki, Leonor Arenillas, J M Hernández, Barbara Hildebrandt, Carmen Pedro, María-Luisa Martín, Esperanza Such, Teresa Vallespi, Javier Grau, Ana Valencia, E. Luño, A.A.N. Giagounidis, Ulrich Germing, Sabine Blum, Michael Pfeilstöcker, Mar Mallo, D. Haase, Blanca Espinet, C. Fonatsch, and Francesc Solé
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Fusion gene ,Internal medicine ,medicine ,Humans ,Anemia, Macrocytic ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chromosome Aberrations ,Hematology ,business.industry ,Anemia, Macrocytic/genetics ,Anemia, Macrocytic/mortality ,Chromosome Deletion ,Chromosomes, Human, Pair 5/genetics ,Female ,Karyotyping ,Middle Aged ,Myelodysplastic Syndromes/genetics ,Myelodysplastic Syndromes/mortality ,Prognosis ,Myelodysplastic syndromes ,Cytogenetics ,Myeloid leukemia ,De novo Myelodysplastic Syndrome ,medicine.disease ,Lymphoma ,Leukemia ,Myelodysplastic Syndromes ,Chromosomes, Human, Pair 5 ,business - Abstract
This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q. Additional chromosomal abnormalities were strongly related to different patients' characteristics. In multivariate analysis, the most important predictors of both OS and AML transformation risk were number of chromosomal abnormalities (P
- Published
- 2010
41. Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM)
- Author
-
K. Hauck, David Lopez, Carlo Aul, Rainer Haas, Aristoteles Giagounidis, Ariane Dienst, Markus Heinsch, Judith Strapatsas, Mathias J. Rummel, Elias K. Mai, Julia Baier, Svenja Liesenjohann, Celina Gerrlich, Hartmut Goldschmidt, Edwin Boelke, Amelie Boquoi, Roland Fenk, Mustafa Kondakci, Guido Kobbe, and Nicolaus Kröger
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Autologous blood ,Newly diagnosed ,medicine.disease ,Consolidation therapy ,Transplantation ,03 medical and health sciences ,0302 clinical medicine ,Maintenance therapy ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Stem cell ,business ,Multiple myeloma ,030215 immunology ,Lenalidomide ,medicine.drug - Abstract
8016Background: While Len MT after high-dose therapy (HDT) and autologous blood stem cell transplantation (aBSCT) is standard of care in pts with MM, optimal dosage has not been established. Method...
- Published
- 2018
42. Von tödlicher Blutungsneigung zu lebensbedrohlicher Thrombosegefährdung – Neue Komplikationen einer «sanften» Behandlung akuter Promyelozytenleukämien mit all-trans-Retinsäure
- Author
-
Schneider W, Runde, and Carlo Aul
- Subjects
medicine.medical_specialty ,Hemorrhagic diathesis ,business.industry ,All trans ,Retinoic acid ,General Medicine ,Gastroenterology ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Anesthesia ,medicine ,business ,Thrombotic complication - Published
- 2009
43. Diagnostik der myelodysplastischen Syndrome (»Präleukämien«)
- Author
-
J T Fischer, W. Schneider, and Carlo Aul
- Subjects
medicine.medical_specialty ,Pathology ,business.industry ,Myelodysplastic syndromes ,Preleukemia ,medicine ,General Medicine ,medicine.disease ,business ,Pancytopenia ,Dermatology ,Hemorrhagic disorder - Published
- 2008
44. Zytologisch-zytochemische Methoden in der Klassifikation akuter Leukämien
- Author
-
W. Schneider, Carlo Aul, and J T Fischer
- Subjects
General Medicine - Published
- 2008
45. Therapie der myelodysplastischen Syndrome
- Author
-
Carlo Aul, Norbert Gattermann, Wolfgang Schneider, and Axel Heyll
- Subjects
Text mining ,business.industry ,Myelodysplastic syndromes ,medicine ,General Medicine ,business ,Bioinformatics ,medicine.disease - Published
- 2008
46. Atypische Gelenksymptomatik als Erstsymptom einer Varizelleninfektion bei chronischer myeloischer Leukämie
- Author
-
Wolfgang Schneider, Carlo Aul, M Arning, K. F. Bürrig, and Petra Reinecke
- Subjects
Hepatitis ,medicine.medical_specialty ,business.industry ,Fulminant ,Autopsy ,General Medicine ,medicine.disease ,Trunk ,High fever ,Dermatology ,Surgery ,Leukemia ,Myelogenous ,Herpetiform ,Medicine ,business - Abstract
A 25-year-old man, known to have chronic myeloid leukaemia for four years, acutely developed a fever of 39.5 degrees and severe pain in the shoulder and hip joints. There was no evidence of joint disease. Treatment with indomethacin briefly improved the symptoms, but within 72 hours the patient developed a fulminant illness with high fever and clinical as well as biochemical signs of a severe consumption coagulopathy. Herpetiform efflorescences appeared over the head and trunk shortly before death. At autopsy there was histological and immunohistochemical evidence of a varicella infection with hepatitis, oesophageal involvement and severe internal organ bleedings. In immune-compromised patients with atypical prodromal symptoms a varicella infection must be considered so that causal treatment with acyclovir and hyperimmune-globulin can be begun in time.
- Published
- 2008
47. Differentialtherapie der thrombotisch-thrombozytopenischen Purpura: Frischplasmagabe versus Plasmaseparation
- Author
-
Carlo Aul, Bernd Grabensee, Königshausen T, R. E. Scharf, and H. Küppers
- Subjects
Coma ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,General Medicine ,Haemolysis ,Gastroenterology ,Purpura ,Elevated igg ,Internal medicine ,Immunology ,medicine ,Platelet ,Plasmapheresis ,Platelet activation ,Microangiopathic haemolytic anaemia ,medicine.symptom ,business - Abstract
In a 29-year-old man with primary thrombotic-thrombocytopenic purpura a significantly increased plasma concentration of platelet-specific proteins was demonstrated as an expression of increased intravascular platelet activation and destruction during the acute phase of the disease. There was also abnormally elevated IgG loading of platelets. During administration of fresh plasma alone (total of six litres over one week) the clinical state deteriorated further into coma and failure of spontaneous ventilation. The marked thrombocytopenia and microangiopathic haemolytic anaemia remained unchanged. Only after repeated plasmapheresis was it possible to break through the acute disease process. Remission (restoration of vital functions, normalization of platelet count and haemolysis signs) was achieved after five courses of plasmapheresis with a total exchange volume of 20 litres. At least in this case, the therapeutic success of plasmapheresis argues for an immunological-toxic genesis of thrombotic-thrombocytopenic purpura.
- Published
- 2008
48. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
- Author
-
Reinhard Stauder, Thomas Müller, Friedrich Wimazal, Thomas Nösslinger, Otto Krieger, Ulrich Germing, Detlef Haase, Barbara Hildebrandt, Julie Schanz, Michael Pfeilstöcker, Regina Kunzmann, Christian Steidl, Lorenz Trümper, Peter Valent, Carlo Aul, Christa Fonatsch, Andrea Kündgen, Michael Lübbert, and Aristoteles Giagounidis
- Subjects
Oncology ,medicine.medical_specialty ,Monosomy ,Pathology ,Databases, Factual ,Immunology ,Biology ,Biochemistry ,03 medical and health sciences ,Chromosome 15 ,0302 clinical medicine ,Germany ,Internal medicine ,medicine ,Humans ,Chromosome Aberrations ,De novo Myelodysplastic Syndrome ,Karyotype ,Cell Biology ,Hematology ,Classification ,Prognosis ,medicine.disease ,3. Good health ,Survival Rate ,International Prognostic Scoring System ,Austria ,Karyotyping ,Myelodysplastic Syndromes ,030220 oncology & carcinogenesis ,Cytogenetic Analysis ,Chromosome abnormality ,Chromosome 21 ,Trisomy ,030215 immunology - Abstract
We have generated a large, unique database that includes morphologic, clinical, cytogenetic, and follow-up data from 2124 patients with myelodysplastic syndromes (MDSs) at 4 institutions in Austria and 4 in Germany. Cytogenetic analyses were successfully performed in 2072 (97.6%) patients, revealing clonal abnormalities in 1084 (52.3%) patients. Numeric and structural chromosomal abnormalities were documented for each patient and subdivided further according to the number of additional abnormalities. Thus, 684 different cytogenetic categories were identified. The impact of the karyotype on the natural course of the disease was studied in 1286 patients treated with supportive care only. Median survival was 53.4 months for patients with normal karyotypes (n = 612) and 8.7 months for those with complex anomalies (n = 166). A total of 13 rare abnormalities were identified with good (+1/+1q, t(1q), t(7q), del(9q), del(12p), chromosome 15 anomalies, t(17q), monosomy 21, trisomy 21, and −X), intermediate (del(11q), chromosome 19 anomalies), or poor (t(5q)) prognostic impact, respectively. The prognostic relevance of additional abnormalities varied considerably depending on the chromosomes affected. For all World Health Organization (WHO) and French-American-British (FAB) classification system subtypes, the karyotype provided additional prognostic information. Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS.
- Published
- 2007
49. Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes
- Author
-
Carlo Aul, Friedrich Wimazal, Barbara Hildebrandt, Andrea Kuendgen, Julie Schanz, Ulrich Germing, Detlef Haase, Lorenz Trümper, Michael Pfeilstöcker, Reinhard Stauder, Regina Kunzmann, Thomas Nösslinger, Otto Krieger, Aristoteles Giagounidis, Christian Steidl, Peter Valent, Christa Fonatsch, Michael Lübbert, and Thomas Müller
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Poor risk ,Multivariate analysis ,business.industry ,Myelodysplastic syndromes ,Cytogenetics ,General Medicine ,Blast Count ,medicine.disease ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,International Prognostic Scoring System ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Bone marrow ,business ,030215 immunology ,French–American–British classification - Abstract
The International Prognostic Scoring System (IPSS) for myelodysplastic syndromes (MDS) identifies bone marrow (BM) blasts, cytogenetics, and the number of cytopenias as major variables with impact on disease outcome. Weighting of these variables defines distinct subgroups using multivariate analysis approaches. Recent studies, including the work of our group, indicate an underestimation of unfavorable cytogenetics in the IPSS. To delineate the prognostic impact of poor-risk karyotypes in relation to blast counts, we studied clinical outcome of cytogenetic and blast count subgroups in a large cohort of 1440 patients with MDS. Using univariate analytic tools, median survival times of 158 patients with poor-risk cytogenetics and 66 patients with blast counts of > 20% were 11.1 months and 9 months, respectively. Median survival times of patients with poor-risk cytogenetics and normal blast counts (n = 60; median survival, 17 months) were not significantly different from those of good-risk karyotypes and highly elevated BM blasts (11%–20%: n = 89; median survival, 22 months; P = .098; > 20%: n = 32; median survival, 13 months; P = .892). Our data indicate an equal prognostic significance of poor-risk cytogenetics compared with highly elevated BM blasts and suggest a higher score for unfavorable karyotypes in future integrative prognostic systems in MDS.
- Published
- 2007
50. Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification
- Author
-
Yasushi Miyazaki, Hideki Tsushima, Masako Iwanaga, Corinna Strupp, Carlo Aul, Motohiro Misumi, Mari Sakai, Norbert Gattermann, Akira Matsuda, Ulrich Germing, Itsuro Jinnai, Masami Bessho, Masao Tomonaga, and Andrea Kuendgen
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,World Health Organization ,Gastroenterology ,Japan ,Germany ,Internal medicine ,Humans ,Medicine ,Survivors ,Survival analysis ,Cytopenia ,Univariate analysis ,Hematology ,business.industry ,Myelodysplastic syndromes ,Chromosome Mapping ,Anemia ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Oncology ,Dysplasia ,Myelodysplastic Syndromes ,Female ,business ,Refractory cytopenia with multilineage dysplasia ,Megakaryocytes ,French–American–British classification - Abstract
In the criteria of refractory cytopenia with multilineage dysplasia (RCMD) according to the WHO (World Health Organization) classification, the frequency threshold concerning dysplasia of each lineage was defined as 10%. To predict overall survival (OS) and leukemia-free survival (LFS) for patients with refractory anemia (RA) according to the French-American-British (FAB) classification, we investigated prognostic factors based on the morphological features of 100 Japanese and 87 German FAB-RA patients, excluding 5q-syndrome. In the univariate analysis of all patients, pseudo-Pelger-Huet anomaliesor=10% (Pelger+), micromegakaryocytesor=10% (mMgk+), dysgranulopoiesis (dys G)or=10% and dysmegakaryopoiesis (dys Mgk)or=40% were unfavorable prognostic factors for OS and LFS (OS; P0.001, LFS; P0.001). The prognostic effects of the morphological features were similar in both Japanese and German patients. However, dys Mgkor=10% was not correlated with OS and LFS. In the multivariate analysis, mMgk+ and dys Mgkor=40% were adverse prognostic factors for OS for all patients, and dys Gor=10% and dys Mgkor=40% were adverse prognostic factors for LFS for all patients. On the basis of the present analysis, we propose the following modified morphological criteria for RCMD. Modified RCMD should be defined as FAB-RA, excluding 5q-syndrome with dys Gor=10%, dys Mgkor=40% or mMgk+.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.